Leflutrozole
Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men. It was also under investigation for the treatment of endometriosis, but development for this indication was discontinued. As of December 2017, leflutrozole is in phase II clinical trials for hypogonadism.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329037297 under CC BY-SA 4.0; modifications have been made.